
Sign up to save your podcasts
Or


AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops
Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B
Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals
- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
- OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline
- Sarepta's big bet on Arrowhead's siRNA assets yields early data
From the publisher's feed